1. Introduction {#sec1}
===============

Synchronous primary neoplasms are defined when two or more neoplasms take place concurrently in the same patient. These neoplasms should be histologically discrete and separated from each other by means of healthy tissues, such as basal lamina or stroma \[[@B1]\]. Double gynecological neoplasms are occasionally observed, and the most commonly reported combination is endometrial-ovarian neoplasms \[[@B2], [@B3]\]. The incidence of triple or more synchronous primary neoplasms of the female genital system is exceedingly uncommon. To the best of our knowledge, only 13 such cases have been reported in the PubMed-indexed English literature \[[@B1], [@B2], [@B4]--[@B14]\]. Herein, we report a single case of triple synchronous primary neoplasms of the cervix, endometrium, and right ovary with three distinct histological patterns that were not reported previously. Moreover, we briefly present a summary table of all English PubMed-indexed existing cases of triple or more synchronous primary neoplasms of the female genital system (*n* = 13).

2. Case Report {#sec2}
==============

A 55-year-old multiparous woman was referred to our hospital as a case of pelvic/abdominal mass for 2 months. The mass was associated with progressive abdominal distention, left lower abdominal pain, and occasional vaginal bleeding. Her past medical and surgical histories were unremarkable. Upon pelvic examination, a cystic, mobile, nontender pelvic mass was palpated up to the umbilicus. There were no abnormal cervical growths. Laboratory findings showed a slightly elevated CA-125 level of 36.6 U/mL (normal range: 0--35 U/mL).

Two imaging studies were conducted: ultrasound (US) and computed tomography (CT) scan. US showed a 15 cm pelvic mass at the left adnexal site. The mass was cystic and contained solid areas. CT scan showed a heterogeneous 14 × 12 cm pelvic/abdominal mass with solid components, along with multiple prominent left pelvic and para-aortic lymph nodes that were highly suspicious for metastasis. The mass was seen between uterus and rectum. The mass was most likely originating from the left ovary and inseparable from the posterior uterus ([Figure 1](#fig1){ref-type="fig"}). In view of an underlying neoplastic process, a surgical staging operation was planned.

The surgical staging operation consisted of total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy, sampling from the pelvic lymph nodes and para-aortic lymph nodes, and multiple biopsy specimens from various peritoneal sites. During the laparotomy, the pelvic mass was found to be most likely originating from the left ovary. The uterus was bulky and the right ovary was grossly normal. There were no ascites or other gross intra-abdominal lesions. All resected specimens were examined for histopathological analysis.

Histopathological examination showed grade-I endometrioid adenocarcinoma of the uterus with no lymphovascular invasion and less than 50% invasion into the myometrium ([Figure 2](#fig2){ref-type="fig"}). Both ovaries were examined, and the microscopic appearance of the left ovary revealed clear-cell carcinoma with no lymphovascular invasion ([Figure 3](#fig3){ref-type="fig"}). The right ovary and bilateral fallopian tubes were normal. Microscopic examination of the cervix exhibited poorly differentiated squamous cell carcinoma ([Figure 4](#fig4){ref-type="fig"}). The omentum and bilateral pelvic and para-aortic lymph nodes were negative for metastasis.

Therefore, the final histopathological diagnosis was triple synchronous primary stage 1B1 poorly differentiated squamous cell carcinoma of the cervix (pTNM: T1B1 Nx M0), stage 1A grade-I endometrioid adenocarcinoma of the uterus (pTNM: T1A Nx M0), and stage 1A clear-cell carcinoma of the left ovary (pTNM: T1A Nx M0).

The case was discussed in the multidisciplinary tumor board meeting and the recommendation was to start adjuvant therapy. The adjuvant therapy consisted of chemotherapy and radiation therapy. The adjuvant chemotherapy was primarily intended for the high-risk ovarian cancer (clear-cell carcinoma) and included six cycles of paclitaxel 175 mg/m^2^ plus carboplatin (area under the curve \[AUC\] 6). The adjuvant radiation therapy was primarily intended for the high-risk cervical cancer (poorly differentiated squamous cell carcinoma) and consisted of external beam radiation therapy (EBRT) of 51 Gy delivered in 26 fractions.

The management plan was discussed with the patient; however, she refused the adjuvant treatment. Three months later, she presented to clinic with radiological evidence of recurrence, as follows: large local recurrence in the left iliac fossa, multiple metastatic masses in the abdominal and pelvic cavities, and multiple metastatic retroperitoneal and pelvic lymph nodes.

3. Discussion {#sec3}
=============

The incidence rate of double synchronous primary gynecological neoplasms is relatively uncommon and ranges from 0.6% to 5.4% \[[@B2], [@B3], [@B15]--[@B17]\]. The incidence rate of triple or more synchronous primary neoplasms of the female genital system is exceedingly uncommon. To the best of our knowledge, only 13 such cases have been reported in the PubMed-indexed English literature \[[@B1], [@B2], [@B4]--[@B14]\] ([Table 1](#tab1){ref-type="table"}). There was only one case of quintuple synchronous neoplasms \[[@B10]\] and two cases of quadruple synchronous neoplasms \[[@B8], [@B11]\]. On the other hand, there were only 10 cases of triple synchronous neoplasms. In our study, the distinctive combination of poorly differentiated squamous cell carcinoma of the cervix, grade-I endometrioid adenocarcinoma of the uterus and clear-cell carcinoma of the left ovary has never been previously reported.

The etiology of synchronous primary neoplasms of the female genital system remains poorly defined. It has been assumed that in genetically predisposed individuals, the Mullerian tissues with similar embryological origin may respond as a single structural entity when simultaneously exposed to carcinogenic, hormonal, therapeutic, or other triggering factors \[[@B2]\]. In our study, there were three different histological subtypes identified in the surgical specimens (squamous, endometrioid, and clear-cell). This unusual presentation raises thoughts about potential underlying epigenetic/bimolecular explanations, and this is an interesting arena for future research.

Several clinicopathological criteria have been suggested to assist clinicians and pathologists in distinguishing synchronous primary gynecological neoplasms from related metastatic foci. These criteria include either one major criterion or all the four minor criteria. The one major criterion is the existence of distinct histological types of the neoplasms. The four minor criteria include (a) neoplasms which are limited to primary locations, (b) absence of direct extension between neoplasms, (c) absence of lymphovascular neoplastic invasion, and (d) absence of distant metastasis \[[@B18], [@B19]\]. In our case, all the above-mentioned major and minor criteria were met, hence confirming the diagnosis of triple synchronous primary neoplasms of the female genital system.

It is critically crucial to differentiate between synchronous primary gynecological neoplasms and related metastatic diseases. This is because both management and prognosis vary substantially. Regarding prognosis, synchronous primary gynecological neoplasms are associated with better survival rates than metastatic or advanced primary ones \[[@B2], [@B3], [@B17]\]. This observation may be attributable to the younger age of presentation, earlier disease stage, and lower disease grade at the time of clinical diagnosis \[[@B17]\]. The prognosis of a triple neoplasm is largely determined by the neoplasm with the poorest prognosis \[[@B5]\].

There are no specific guidelines regarding the management of synchronous primary gynecological neoplasms. Proper management should be largely individualized taking into consideration several parameters, such as age of patient, disease type, disease stage, disease grade, and extent of the neoplastic invasion \[[@B10]\]. Management modalities include surgical debulking and/or adjuvant radiotherapy and/or adjuvant chemotherapy, as seen clinically appropriate. Patients with advanced stage, higher grade, and poor histological synchronous primary neoplasms should be treated with more aggressive management modalities.

Clear-cell carcinoma (CCC) of the ovary is regarded as a grade III and high-risk neoplasm, irrespective of the disease stage. Also, CCC of the ovary is recognized to be less sensitive to first-line platinum-based chemotherapy \[[@B20]\]. Previous evidence advocated that irinotecan was more effective against primary \[[@B21]\] and recurrent \[[@B22]\] ovarian CCC when compared to other cytotoxic regimens. However, a recent randomized phase III trial of paclitaxel plus carboplatin (PC) versus irinotecan plus cisplatin (CPT-P) in patients with ovarian CCC showed no superiority of CPT-P over the gold standard PC regimen \[[@B23]\].

Poorly differentiated squamous cell carcinoma of the cervix is regarded as a high-risk factor influencing the likelihood of recurrence. Hence, an adjuvant therapy may be recommended. The administration of concurrent cisplatin-based chemotherapy and radiation therapy (in the form of EBRT or brachytherapy) has been shown to substantially improve progression-free and overall survival for high-risk, early-stage patients with cervical cancer \[[@B24]\].

4. Conclusion {#sec4}
=============

Although exceedingly uncommon, the likelihood of triple synchronous primary neoplasms should be considered when evaluating neoplasms of the female genital system. Careful pathological examination of the surgical specimens can substantially aid in recognizing such synchronous neoplasms.
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###### 

A summary table of all existing cases of triple or more synchronous primary neoplasms of the female genital system (*n* = 13).

  Ref                    Author                    Year                          Age (yr)   Presentation                 Site     Tumor histology                                    Tx     FU (mon)   Outcome
  ---------------------- ------------------------- ----------------------------- ---------- ---------------------------- -------- -------------------------------------------------- ------ ---------- ---------
                                                                                            Anorexia                     Ovary    Papillary serous cystadenocarcinoma                                   
  \[[@B14]\]             Matlock et al.            1982                          77         Abdominal pain               Ovary    Mucinous cystadenocarcinoma                        CT     4          DOD
                                                                                            Weight loss                  Uterus   papillary adenocarcinoma with psammoma bodies                         
                                                                                                                                                                                                       
                                                                                            NM                           Ovary    Mucinous adenocarcinoma                                               
  \[[@B2]\]              Ayhan et al.              1992                          NM                                      Uterus   Endometrioid adenocarcinoma                        NM     28         DOD
                                                                                                                         Cervix   Carcinoma in situ                                                     
                                                                                                                                                                                                       
                                                                                            Vaginal bleeding             Ovary    Endometrioid adenocarcinoma                                           
  \[[@B7]\]              Jobo et al.               1997                          35                                      Uterus   Endometrioid adenocarcinoma                        CT     25         NED
                                                                                                                         Cervix   Carcinoma in situ                                                     
                                                                                                                                                                                                       
                                                                                            Vaginal bleeding             Ovary    Clear-cell carcinoma                                                  
  \[[@B1]\]              Ree et al.                2003                          46                                      Ovary    Borderline mucinous cystadenoma                    CT     17         NED
                                                                                                                         Uterus   Endometrioid adenocarcinoma                                           
                                                                                                                                                                                                       
                                                                                            Pelvic pain                  Ovary    Mucinous adenocarcinoma                                               
  \[[@B9]\]              Isin Dogan Ekici et al.   2006                          56         Vaginal bleeding             Uterus   Endometrioid adenocarcinoma                        CT     24         NED
                                                                                                                         Uterus   Leiomyosarcoma                                                        
                                                                                                                                                                                                       
                                                                                            Menorrhagia                  Ovary    Mucinous adenocarcinoma                                               
  \[[@B11]\]             Phupong et al.            2007                          50                                      Ovary    Low malignant potential                            RT     3          DOD
                         Uterus                    Endometrioid adenocarcinoma                                                                                                                         
                                                                                                                         Cervix   Endocervical adenosquamous carcinoma                                  
                                                                                                                                                                                                       
                                                                                            Spotting                     Ovary    Brenner tumor                                                         
  \[[@B13]\]             Pekin et al.              2007                          62         Vaginal bleeding             Ovary    Granulosa tumor                                    NM     NM         NM
                                                                                                                         Cervix   Squamous cell carcinoma                                               
                                                                                                                                                                                                       
                                                                                            Postmenopausal bleeding      Ovary    Mucinous adenocarcinoma                                               
  \[[@B8]\]              Saglam et al.             2008                          63                                      FT       Early papillary adenocarcinoma                     CT     12         NED
  Abdominal distention   Uterus                    Endometrioid adenocarcinoma                                                                                                                         
                                                                                                                         Cervix   Endocervical adenocarcinoma                                          
                                                                                                                                                                                                       
                                                                                            Pelvic pain                  Ovary    Papillary serous adenocarcinoma                                       
                                                                                            Lower abdominal distention   FT       Microinvasive carcinoma in situ                                       
  \[[@B10]\]             Atasever et al.           2009                          50                                      FT       Microinvasive carcinoma in situ                    CT     29         DOD
                                                                                                                         Uterus   Intraepithelial adenocarcinoma                                        
                                                                                                                         Cervix   Endocervical in situ carcinoma                                        
                                                                                                                                                                                                       
                                                                                            Fatigue                      Ovary    Mucinous, clear cell, and endometrioid carcinoma                      
  \[[@B6]\]              Hale et al.               2011                          49         Ankle edema                  Uterus   Endometrioid adenocarcinoma                        NM     NM         NM
                                                                                            Abdominal distention         Cervix   Endometrioid adenocarcinoma                                           
                                                                                                                                                                                                       
                                                                                            Abdominal distention         Ovary    Leydig cell                                                           
  \[[@B12]\]             Zhang and Lerwill         2011                          79         Abdominal pain               Uterus   Myxoid leiomyosarcoma                              None   10         NED
                                                                                            Dyspnea                      Uterus   Mucinous adenocarcinoma                                               
                                                                                                                                                                                                       
                                                                                            Metrorrhagia                 Ovary    Serous adenocarcinoma                                                 
  \[[@B4]\]              Takatori et al.           2014                          50                                      Uterus   Endometrioid adenocarcinoma                        CT     18         NED
                                                                                                                         Cervix   Endometrioid adenocarcinoma                                           
                                                                                                                                                                                                       
                                                                                            Pelvic pain                  Ovary    Mucinous adenocarcinoma                                               
  \[[@B5]\]              Chiofalo et al.           2016                          38         Vaginal bleeding             Uterus   Endometrioid adenocarcinoma                        CT     18         NED
                                                                                                                         Cervix   Mucinous adenocarcinoma                                               
                                                                                                                                                                                                       
                                                                                            Abdominal distention         Ovary    Clear-cell carcinoma                                                  
                         Our case                  2017                          55         Abdominal pain               Uterus   Endometrioid adenocarcinoma                        None   3          DP
                                                                                            Vaginal bleeding             Cervix   Poorly differentiated squamous cell carcinoma                         

Ref: reference; yr: years; Tx: therapy; mon: months; CT: chemotherapy; RT: radiotherapy; NM: not mentioned; DOD: died of disease; NED: no evidence of disease; DP: disease progression.
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